CagriSema, a once-weekly combination of the amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide, offers a dual mechanism targeting both appetite suppression and glycemic regulation.
Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with T2Ds.
Novo Nordisk expects to file for regulatory approval for CagriSema in the first quarter of 2026 and is running a range of large studies to determine how much the drug can help patients, including a head-to-head trial with Lilly’s ZEPBOUND.
At the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Novo Nordisk unveiled ...
